Alpha Cognition to Present New Clinical Data on ZUNVEYL® at Upcoming Alzheimer’s-Focused Conferences
Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” or the “Company”), a commercial-stage biopharmaceutical company dedicated to advancing therapies for neurodegenerative diseases, announced today that it will present new clinical data on ZUNVEYL® (Benzgalantamine) at two major upcoming scientific conferences focused on the treatment and management of Alzheimer’s disease and related dementias. These presentations underscore the company’s commitment to improving patient outcomes through innovative pharmacological approaches and a deeper understanding of the underlying mechanisms of cognitive decline in neurodegenerative disorders.
The first of these events is the American Association of Geriatric Psychiatrists (AAGP) Annual Meeting, taking place from April 16–20, 2026. The AAGP meeting is one of the premier gatherings of healthcare professionals dedicated to understanding and treating psychiatric disorders in older adults, with a particular focus on dementia-related conditions, depression, and other neurocognitive disorders. Alpha Cognition’s participation in this event demonstrates the company’s dedication to engaging with clinicians and researchers who are on the front lines of treating Alzheimer’s disease and related dementias.
The second event is the Neuroscience Education Institute (NEI) Spring Congress, scheduled for May 1–3, 2026. NEI is widely recognized for its efforts in advancing neuroscience education among healthcare professionals, offering a platform for sharing the latest scientific insights and therapeutic strategies in the treatment of neurodegenerative diseases. By presenting at both AAGP and NEI, Alpha Cognition will reach a broad audience of neurologists, geriatric psychiatrists, pharmacologists, and other key stakeholders in dementia care, facilitating dialogue and collaboration around emerging therapies such as ZUNVEYL.
Alpha Cognition will share four key poster presentations at these conferences, highlighting the latest clinical and literature-based insights into the use of acetylcholinesterase inhibitors (AChEIs), including ZUNVEYL, in the management of Alzheimer’s disease:
- Beyond Cholinesterase Inhibition: The Clinical Benefits of Galantamine- and Benzgalantamine-Mediated Nicotinic Receptor Modulation in Alzheimer’s Disease
Presenter: Kurt Grady, PharmD (Poster S49)
Presentation: April 18, 5:30 PM EST This poster explores the multifaceted mechanism of action of benzgalantamine, the active compound in ZUNVEYL. While traditional AChEIs focus primarily on inhibiting the breakdown of acetylcholine to enhance cognitive function, benzgalantamine has been shown to also modulate nicotinic acetylcholine receptors. This dual action may provide broader cognitive and functional benefits for patients with Alzheimer’s disease, including potential improvements in attention, memory, and overall neural network connectivity. Dr. Grady’s presentation will highlight clinical trial data demonstrating how this receptor modulation contributes to enhanced cognitive outcomes beyond standard cholinesterase inhibition. - Literature Review: Acetylcholinesterase Inhibitors and Delayed Nursing Home Placement in Alzheimer’s Disease
Presenter: Pavel Svintozelskiy, PharmD (Poster S45)
Presentation: April 18, 5:30 PM EST In this literature review, Dr. Svintozelskiy examines evidence from multiple clinical studies assessing the long-term impact of AChEI therapy on delaying institutionalization among Alzheimer’s patients. Findings indicate that sustained use of AChEIs, including benzgalantamine-based therapies, can meaningfully extend the duration of home-based care, thereby improving quality of life for both patients and caregivers. This review emphasizes the socio-economic and emotional benefits of prolonged therapy and supports the strategic use of ZUNVEYL as part of a comprehensive care plan for Alzheimer’s patients. - Acetylcholinesterase Inhibitors and Psychotropic Medication Use in Alzheimer’s Disease and Related Dementias (ADRD)
Presenter: Pavel Svintozelskiy, PharmD
Presentation: May 2, 9:45 AM EST This poster examines the relationship between AChEI therapy and the utilization of psychotropic medications, which are often prescribed to manage behavioral and psychiatric symptoms in patients with ADRD. Dr. Svintozelskiy’s analysis indicates that effective AChEI therapy, such as that provided by ZUNVEYL, may reduce the need for additional psychotropic interventions, potentially lowering the risk of adverse side effects associated with polypharmacy in elderly populations. These findings highlight an important clinical consideration: integrating targeted AChEI therapy can enhance overall patient management by stabilizing neuropsychiatric symptoms and reducing reliance on adjunctive pharmacotherapy. - Acetylcholinesterase Inhibitor Persistence: The Value of Sustained Therapy in Alzheimer’s Disease and Related Dementias
Presenter: Kurt Grady, PharmD
Presentation: May 2, 9:45 AM EST Persistence with AChEI therapy is a critical factor in achieving optimal clinical outcomes. Dr. Grady’s poster presentation will detail real-world data illustrating the benefits of continued ZUNVEYL administration over extended periods. Sustained therapy has been associated with improved cognitive performance, enhanced daily functioning, and overall slower disease progression. The presentation underscores the importance of patient adherence and proactive management strategies to maximize the therapeutic value of benzgalantamine in clinical practice.
Dennis Kay, PhD, Chief Scientific Officer of Alpha Cognition, commented on the upcoming presentations:
We’re excited to present new data on ZUNVEYL at these upcoming conferences, further characterizing its clinical profile in patients with Alzheimer’s disease. These findings build on our understanding of ZUNVEYL’s potential and reinforce our commitment to improving outcomes for patients and caregivers through innovative approaches. We look forward to engaging with the scientific and medical community as we continue to support its integration into real-world treatment settings.”
ZUNVEYL represents a significant advancement in the field of Alzheimer’s therapeutics. Its dual mechanism of action, combining acetylcholinesterase inhibition with nicotinic receptor modulation, provides a unique clinical profile that may address both cognitive and functional deficits associated with the disease. By presenting these data at both AAGP and NEI, Alpha Cognition aims to disseminate insights that may inform clinical decision-making, enhance patient care strategies, and ultimately contribute to better long-term outcomes for individuals living with Alzheimer’s disease.
Alpha Cognition’s ongoing research and engagement with the medical community reflect the company’s broader mission: to develop therapies that meaningfully improve the lives of patients affected by neurodegenerative diseases while providing support and resources to caregivers. With the upcoming poster presentations, the company continues to advance its commitment to scientific rigor, clinical innovation, and the pursuit of therapeutic solutions that address the complex challenges of Alzheimer’s disease and related dementias.